There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the FDA at a manufacturing plant run by South Korea’s Celltrion.
After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial.
Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a
